Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank74
3Y CAGR-47.9%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-47.9%/yr
Quarterly compound
Percentile
P74
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.88% |
| Q3 2025 | 162.13% |
| Q2 2025 | -42.30% |
| Q1 2025 | 6.90% |
| Q4 2024 | -156.38% |
| Q3 2024 | 39.93% |
| Q2 2024 | 61.88% |
| Q1 2024 | 3.93% |
| Q4 2023 | -21.55% |
| Q3 2023 | -35.83% |
| Q2 2023 | -8.45% |
| Q1 2023 | -102.04% |
| Q4 2022 | 41.57% |
| Q3 2022 | -336.98% |
| Q2 2022 | 72.14% |
| Q1 2022 | -26.11% |
| Q4 2021 | -270.43% |
| Q3 2021 | -65.39% |
| Q2 2021 | 274.25% |
| Q1 2021 | -17.79% |
| Q4 2020 | -52.36% |
| Q3 2020 | -157.02% |
| Q2 2020 | -28.11% |
| Q1 2020 | -147.64% |
| Q4 2019 | -41.40% |
| Q3 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |